Polyoxygenin (Polyoxidin)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substancePotassium iodide + Sodium chloride + MacrogolPotassium iodide + Sodium chloride + Macrogol
Similar drugsTo uncover
  • Polyoxygenin
    solution d / infusion 
    KRASFARMA, JSC     Russia
    • Dosage form: & nbspsolution for infusions
    Composition:

    Macrogol (polyethylene glycol 20000) - 15.0 g

    Sodium Chloride - 9.0 g

    potassium iodide 0.5 g

    water for injection - up to 1 liter

    theoretical osmolarity - 314 mosm / l

    Description:Transparent colorless liquid.
    Pharmacotherapeutic group:Plasmasuberant
    ATX: & nbsp

    B.05.A.A   Blood plasma preparations and plasma-substituting drugs

    Pharmacodynamics:

    Combined drug, has a plasma-substituting, antiaggregant, anti-shock effect. Replenishes the volume of circulating blood. It is based on a synthetic polymer in a 0.9% solution of sodium chloride. The molecular weight of the polymer is 20,000 daltons, the polydispersity coefficient Mw|Mn = 1.0-1.9. Polyoxidin is isotonic and isoncotic with blood plasma. Due to the ability of the colloidal basis of the drug to retain fluid in the vascular bed, after the infusion the volume of circulating blood increases, and as a result, - and cardiac output. Polyoxidin reduces the viscosity of blood by reducing the viscosity of plasma and drug-induced hemodilution. The drug has a disaggregating effect on the blood elements. Polyoxidin restores peripheral circulation, improves oxygen transport to tissues, thereby reducing tissue hypoxia,there is a correction of the acid-base state.

    Pharmacokinetics:

    Within 5 days, 95% of the drug is excreted in the urine, about 5% - through the gastrointestinal tract.

    Indications:

    Hypovolemia (acute blood loss, post-traumatic and postoperative shock).

    Contraindications:

    Hypersensitivity to the components of the drug, craniocerebral trauma, intracranial hypertension, arterial hypertension, chronic heart failure II-III Art.

    Pregnancy and lactation:

    The use of the drug during pregnancy and during lactation has not been specifically investigated, therefore safety of its use in such patients is not established.

    Dosing and Administration:

    With the development of shock - intravenously struino, 100-400 ml; if necessary, up to 1200 ml. The rate of administration is determined by the patient's condition, the amount of arterial and venous pressure, the pulse rate and hematocrit. After normalization of arterial pressure, they pass to the drip route of administration. When blood loss is more than 500-700 ml and severe anemia, the transfusion of polyoxydin is combined with blood transfusion. As the central venous pressure increases, the rate of administration decreases.In operations for the prevention of operational shock - intravenously drip (60-80 cap / min), with the transition to jet injection with a sharp decrease in blood pressure.

    Side effects:

    Hyperthermia, nausea, vomiting, allergic reactions.

    Overdose:

    Overdose phenomena are not recorded.

    Interaction:

    Polyoxydin is compatible with blood, any infusion medium, antishock therapy.

    Special instructions:

    After the transfusion, it is necessary to control blood pressure, hematocrit, hemoglobin, a general blood test, urinalysis, and the state of the blood coagulation system. Transfusion does not exclude the need for other anti-shock measures (anesthesia, the introduction of cardiotonic drugs, vasoconstrictive drugs).

    As the central venous pressure rises, the dose and rate of administration of Polyoxygen are reduced.

    If the recommended speed of injection is exceeded, there may be face hyperemia, sensation of heat, headache, nausea and vomiting. In these cases, the infusion of the drug must be stopped and desensitizing therapy administered.After elimination of side effects, renewal of transfusion with reduced speed is permissible.

    Form release / dosage:

    Solution for infusion.

    Packaging:

    For 200, 400 ml in bottles of glass with a capacity of 250, 450 ml. Each bottle with instructions for use is placed in a pack of cardboard.

    24 bottles of 200 ml or 12 bottles of 400 ml in packs are packed in a box of corrugated cardboard.

    For a hospital: 24 bottles of 200 ml, 12 bottles of 400 ml without packs with 5 instructions for use are placed in a box of corrugated cardboard.

    Storage conditions:

    At a temperature of 10 ° Сдо30 ° С.

    Keep out of the reach of children.

    Shelf life:

    2 years. Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:P N002280 / 01
    Date of registration:08.10.2008
    The owner of the registration certificate:KRASFARMA, JSC KRASFARMA, JSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp08.10.2008
    Illustrated instructions
      Instructions
      Up